Literature DB >> 9721431

Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

S N Sehgal1.   

Abstract

OBJECTIVE: Rapamune is a novel immunosuppressive agent in Phase III clinical trial in renal transplantation. Its unique mechanism of action has created great interest in its use as a biochemical probe of signal transduction pathways that has provided insight into its molecular mechanism of action. This article reviews the current state of our understanding of the mechanism of action of rapamune.

Mesh：

Substances：

Year:  1998        PMID： 9721431     DOI： 10.1016/s0009-9120(98)00045-9

Source DB:  PubMed          Journal:  Clin Biochem        ISSN： 0009-9120            Impact factor:   3.281


  128 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

2.  Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation.

Authors:  E Norsted Gregory; S Codeluppi; J A Gregory; J Steinauer; C I Svensson
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

Review 3.  [Immunomodulation in penetrating keratoplasty. Current status and perspectives].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

Review 4.  Islet transplant: an option for childhood diabetes?

Authors:  E Hathout; J Lakey; J Shapiro
Journal:  Arch Dis Child       Date:  2003-07       Impact factor: 3.791

5.  Case report: Corticosteroid-resistant nephrotic syndrome: treatment with rapamune.

Authors:  Liern Jose Miguel; Graciela V Vallejo
Journal:  Pediatr Nephrol       Date:  2006-09-15       Impact factor: 3.714

6.  Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood.

Authors:  T-G Chen; J Z Chen; X-X Wang
Journal:  Cell Prolif       Date:  2006-04       Impact factor: 6.831

7.  Metastatic Renal Cancer: What Role for Everolimus?

Authors:  Franck A Belibi; Charles L Edelstein
Journal:  Clin Med Rev Oncol       Date:  2010-02-18

8.  IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells.

Authors:  Heth R Turnquist; Tina L Sumpter; Allan Tsung; Alan F Zahorchak; Atsunori Nakao; Gerard J Nau; Foo Y Liew; David A Geller; Angus W Thomson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

Review 9.  mTOR inhibitors and renal allograft: Yin and Yang.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Valentina Masola; Giovanni Gambaro; Antonio Lupo
Journal:  J Nephrol       Date:  2014-05-08       Impact factor: 3.902

Review 10.  Exploiting cellular pathways to develop new treatment strategies for AML.

Authors:  Amir T Fathi; Steven Grant; Judith E Karp
Journal:  Cancer Treat Rev       Date:  2010-01-06       Impact factor: 12.111
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.